Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Cash & Equivalents (2016 - 2025)

Ani Pharmaceuticals (ANIP) has disclosed Cash & Equivalents for 16 consecutive years, with $285.6 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 97.14% to $285.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $285.6 million through Dec 2025, up 97.14% year-over-year, with the annual reading at $285.6 million for FY2025, 97.14% up from the prior year.
  • Cash & Equivalents hit $285.6 million in Q4 2025 for Ani Pharmaceuticals, up from $262.6 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $285.6 million in Q4 2025 to a low of $15.3 million in Q3 2021.
  • Historically, Cash & Equivalents has averaged $136.4 million across 5 years, with a median of $144.9 million in 2024.
  • Biggest five-year swings in Cash & Equivalents: soared 1175.43% in 2021 and later plummeted 51.92% in 2022.
  • Year by year, Cash & Equivalents stood at $100.3 million in 2021, then plummeted by 51.92% to $48.2 million in 2022, then surged by 358.49% to $221.1 million in 2023, then tumbled by 34.49% to $144.9 million in 2024, then surged by 97.14% to $285.6 million in 2025.
  • Business Quant data shows Cash & Equivalents for ANIP at $285.6 million in Q4 2025, $262.6 million in Q3 2025, and $217.8 million in Q2 2025.